Nuwellis, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $422.6K
- Price
- $1.16
- % Change (Daily % change from the live per-ticker quote feed.)
- +3.57%
- Volume
- 226.0K
About
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Quick stats
Shares outstanding364.3K
Computed float2.6K
Float / shares0.7%
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001506492
Websitehttps://www.nuwellis.com
AI Summary
AI-generated1/40
standardbullishearnings
Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin
Nuwellis reported Q2 revenue of $2.0 million, up 14% year-over-year, while gross margin expanded significantly to 76% from 56% due to improved pricing and a transition to contract manufacturing.
The company bolstered its balance sheet with approximately $12.7 million in gross proceeds from recent financings, extending its cash runway through the second quarter of 2027.
Strategic highlights include the appointment of Mike McCormick as President and CEO and the advancement of an FDA label expansion for the Aquadex system to patients weighing 5 kilograms or more.
Red flags
- Operating expenses increased to $4.7 million from $3.9 million in the prior-year period
- Company remains unprofitable with a net loss of $4.8 million in the quarter
- Significant non-cash warrant valuation expense of $1.7 million included in net loss